The present disclosure provides host cells, e.g., bacterial cells, that comprise a methionine decarboxylase enzyme for the treatment of diseases and disorders associated with methionine metabolism in a subject. The disclosure further provides pharmaceutical compositions and methods of treating disorders associated with methionine metabolism, such as homocystinuria.

The invention relates to a pharmaceutical composition containing a PLP-dependent enzyme and optionally its cofactor, pyridoxal phosphate (PLP), and/or a phosphate or non-phosphate precursor of PLP, its use as a drug, its production method and a therapeutic treatment method related to it. The pharmaceutical composition comprises erythrocytes and a pharmaceutically acceptable vehicle, the erythrocytes encapsulating the PLP-dependent enzyme. The PLP-dependent enzyme may be methioninase, tyrosine phenol-lyase, tyrosine aminotransferase or cystathionine beta-synthase.

A composition and method for reversing or preventing age-related metabolic and tissue degenerative changes in individuals. The method includes administering, orally, an effective amount of a first composition having methioninase enzyme. The method further includes administering, by a route other than the oral route, such as a parenteral route, an effective amount of a second composition having methioninase enzyme. The method further includes the steps of orally and/or parentally administering pyridoxal-L-phosphate.

The present disclosure provides host cells, e.g., bacterial cells, that comprise a methionine decarboxylase enzyme for the treatment of diseases and disorders associated with methionine metabolism in a subject. The disclosure further provides pharmaceutical compositions and methods of treating disorders associated with methionine metabolism, such as homocystinuria.

The present disclosure provides non-naturally occurring microbial organisms capable of producing ethylene, ethane, and/or methane, as well was methods for producing ethylene, ethane, and/or methane using the same.

Shielding enzymes are made by modifying the enzyme surface with silica precursors and then depositing silica to a desired thickness while retaining biological activity of the enzyme.

Shielding enzymes are made by modifying the enzyme surface with silica precursors and then depositing silica to a desired thickness while retaining biological activity of the enzyme.

A composition and method for treating cancer in a subject in need thereof. The composition includes recombinant-methioninase-producing bacterial strains that upon oral administration can release recombinant-methioninase in the gut of the subject. The bacterial strains include Escherichia coli bacteria comprising the cloned rMETase gene from Pseudomonas putida using plasmid pATG3131, such as Escherichia coli JM109 strain. The bacteria can be incorporated in the microbiome of the subject and release the recombinant-methioninase.

The present disclosure relates to erythroid cells that have been engineered to express a homocysteine reducing polypeptide, or a variant thereof, or a homocysteine degrading polypeptide, or a variant thereof. The engineered erythroid cells may further comprise an amino acid transporter, for example a homocysteine transporter or a serine transporter, or a cystathionine degrading polypeptide. The engineered erythroid cells of the present disclosure are useful in reducing the level of homocysteine in a subject. The engineered erythroid cells of the present disclosure are further useful in methods of treating homocystinuria.

Embodiment of the present invention discloses a kind of methionine lyase and its encoding gene and biosynthetic method. According to the present invention, the gene encoding methionine lyase as shown in SEQ ID No. 1 is separated from the genome of C. rosea. Embodiment of the present invention further provides an efficient biosynthetic method of methionine lyase, comprising: (1) cloning gene (shown in SEQ ID No.1) encoding methionine degradation enzyme into a yeast expression vector to construct recombinant yeast expression vector; (2) transforming the recombinant yeast expression vector into Saccharomyces cerevisiae to obtain expression strain; (3) inducing the expression strain to express the methionine lyase, collecting induced strains, purifying expressed recombinant methionine lyase. Purity of recombinant methionine lyase prepared according to the present invention is above 90%, and its efficiency of degradating methionine can reach 0.530.0030 M MTL.Math.h.sup.1.Math.mg protein.sup.1.